Ophthalmology

A clinical trial from Norway showed inconclusive results, and challenges in the study design.

Visual complaints during atropine therapy may be reduced by using progressive addition lenses.

A recent quality improvement study demonstrated the potential to enhance ophthalmic telehealth using asynchronous testing, which was effective in subspecialty-level care.

The study reported 6.1% of study patients with NTG had ODD diagnosed using EDI-OCT, compared to the 1.8% – 2.0% reported in the general population.

The implant significantly reduced CRT in patients with RVO-ME, but the study reported no relationship between OCT biomarkers and clinical outcomes.

Myopia progressed slower in the highly aspherical lenslet spectacle subset compared to single vision spectacles during the first 2 stages of the study.

The findings may support the use of macular imaging for monitoring at the time of glaucoma diagnosis and for monitoring the rate of GCC thinning.

Neither the retinal disease nor the VEGF inhibitor type was significantly associated with rhegmatogenous retinal detachment risk.

The mean PCDP was estimated by 2 different methods to be 10.7 years and 10.1 years for open-angle glaucoma.

The post-hoc analysis suggests reliable quantification of photoreceptor loss is an essential tool to evaluate therapeutic efficacy in slowing GA progression.

Two-thirds of eyes achieved a good visual outcome of 20/40 or better after cataract surgery among individuals with T2D.

Difluprednate treatment after AGV implantation resulted in a similar IOP and fewer glaucoma medications compared with prednisolone acetate.

Greater glaucoma polygenic risk was associated with faster structural and functional progression in early POAG, despite individuals receiving more intensive treatment.

The analysis additionally suggested the potential benefits of finerenone in the prevention of required ocular interventions.

A retrospective comparative trial showed that agents including bevacizumab, ranibizumab and aflibercept are linked to similar likelihood of RPE tears.

An analysis of over-the-counter products show not all AMD-targeting supplements match the recommended dosage from the National Institutes of Health.

AI-enabled retinal imaging can accurately predict CVD and death, without the need for blood tests or BP measurement, according to the findings.

A Mediterranean-type diet was associated with slower GA enlargement in a recent post-hoc analysis.

Multivariable models suggest the leading markers of incident DR and progression to PDR were duration of diabetes and use of insulin.

New data indicate a statistically not significant increase in the rate of treatment for PH, but investigators stress its potential clinical importance.

More than 80 000 pterygium excisions in the IRIS Registry suggest young, male, and publicly insured patients had an elevated risk of reoperation within 5 years.

The SpyGlass IOL platform showcased a 45% drop in mean intraocular pressure at 3 months in first-in-human glaucoma trial.

A discussion into safety data from the Phase 3 DERBY and OAKS trials on pegcetacoplan with Dr. Boyer at AAO 2022.

New data from AAO 2022 show how technology may refine a currently inefficient enrollment practice for retina disease assessment.

Two-year results from YOSEMITE and RHINE suggest that the positive results of faricimab for DME in year one carried into second year. Dr. Caroline Baumal joins for an in-depth discussion on the findings.